Description / Scope of the Technical Need.
We are seeking breakthrough and scalable delivery systems, technologies, and platforms with a highly differentiated value proposition for OTC medicines, medical devices, and food supplements.
We are particularly interested in solutions that enhance the delivery and performance of active ingredients, including novel delivery mechanisms, bioavailability or permeability enhancement, controlled-release technologies, increased active loading, taste-masking solutions, targeted delivery, and improved protection or stability of actives, or other approaches that provide a clear advantage over existing technologies.
Solutions should deliver meaningful consumer and product benefits such as better absorption or efficacy, faster onset of action, reduced dosing burden, higher active loading, improved convenience and adherence, and/or the ability to support stronger and more differentiated claims.
Relevant routes of administration mainly include oral, nasal, and topical applications.
Priority will be given to advanced-stage, scalable platforms applicable across multiple active ingredients relevant to Opella portfolio, with demonstrated superiority versus relevant existing technologies .
Background.
We believe that how active ingredients are delivered can be as important as the ingredients themselves in improving consumer outcomes. Advances in delivery technologies can enhance bioavailability, efficacy, onset of action, stability, convenience, and adherence, while enabling more differentiated and consumer-centric health solutions.
Key Success Criteria.
Must-have Requirements.
- Relevant to Opella’s portfolio and consumer health categories.
- Advanced-stage or launch-ready technology, supported by robust performance and science data and, where relevant, clinical evidence demonstrating superiority versus a reference solution.
- Demonstrated formulation, stability, scalability, and manufacturing feasibility.
- Non-invasive delivery systems.
Preferred Requirements.
- Patented, patent-pending, or proprietary technology with a strong and defensible competitive advantage.
- First-to-market solution, with limited equivalent offerings currently available.
- Regulatory feasibility already assessed.
- Demonstrated potential to enable new, stronger, or more differentiated claims.
- Applicability across multiple active ingredients and consumer health categories.
- Evidence of superior performance in clinical studies, where relevant.
Approaches not of interest.
- Generic or widely established delivery technologies with limited differentiation versus current market standards.
- Early-stage technologies lacking robust performance validation beyond proof of concept.
- Injectable, parenteral, or other invasive delivery technologies.
- Solutions without demonstrated formulation, stability, scalability, or manufacturing feasibility.
- Technologies with no clear performance advantage versus reference solution/benchmark
- Technologies with significant unresolved regulatory or safety barriers for consumer health applications.
Target Group.
Adults and children, no specific health conditions
Geographies.
Global
Have a question or simply want to know more?
Any question or adverse reaction related to our products must be addressed via www.sanofi.com.
